CN102917708B - 制备大环内酯和酮内酯及其中间体的方法 - Google Patents

制备大环内酯和酮内酯及其中间体的方法 Download PDF

Info

Publication number
CN102917708B
CN102917708B CN201180026739.4A CN201180026739A CN102917708B CN 102917708 B CN102917708 B CN 102917708B CN 201180026739 A CN201180026739 A CN 201180026739A CN 102917708 B CN102917708 B CN 102917708B
Authority
CN
China
Prior art keywords
compound
formula
acid addition
addition salt
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180026739.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102917708A (zh
Inventor
D·E·佩雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Priority to CN201510604701.0A priority Critical patent/CN105198944B/zh
Publication of CN102917708A publication Critical patent/CN102917708A/zh
Application granted granted Critical
Publication of CN102917708B publication Critical patent/CN102917708B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180026739.4A 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法 Expired - Fee Related CN102917708B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510604701.0A CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34666410P 2010-05-20 2010-05-20
US61/346,664 2010-05-20
PCT/US2011/037330 WO2011146829A1 (en) 2010-05-20 2011-05-20 Processes for preparing macrolides and ketolides and intermediates therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510604701.0A Division CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Publications (2)

Publication Number Publication Date
CN102917708A CN102917708A (zh) 2013-02-06
CN102917708B true CN102917708B (zh) 2015-11-25

Family

ID=44992076

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180026739.4A Expired - Fee Related CN102917708B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法
CN201510604701.0A Expired - Fee Related CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510604701.0A Expired - Fee Related CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Country Status (15)

Country Link
US (4) US9051346B2 (cg-RX-API-DMAC10.html)
EP (1) EP2571506B1 (cg-RX-API-DMAC10.html)
JP (1) JP6184319B2 (cg-RX-API-DMAC10.html)
KR (1) KR101945324B1 (cg-RX-API-DMAC10.html)
CN (2) CN102917708B (cg-RX-API-DMAC10.html)
AU (1) AU2011255464C1 (cg-RX-API-DMAC10.html)
BR (1) BR112012029586A2 (cg-RX-API-DMAC10.html)
CA (1) CA2799937A1 (cg-RX-API-DMAC10.html)
DK (1) DK2571506T3 (cg-RX-API-DMAC10.html)
ES (1) ES2636948T3 (cg-RX-API-DMAC10.html)
IL (1) IL223161A0 (cg-RX-API-DMAC10.html)
PL (1) PL2571506T3 (cg-RX-API-DMAC10.html)
RU (1) RU2608390C2 (cg-RX-API-DMAC10.html)
SI (1) SI2571506T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011146829A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
BR112012029586A2 (pt) * 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
CN103897002A (zh) * 2012-12-31 2014-07-02 菏泽市方明制药有限公司 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) * 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
EP4095146A1 (en) 2013-04-04 2022-11-30 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
JP2017531663A (ja) * 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN106554381A (zh) * 2015-09-25 2017-04-05 苏州鹏旭医药科技有限公司 酮内酯类抗生素中间体及其制备方法和应用
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1343216A (zh) * 1999-04-08 2002-04-03 北陆制药株式会社 红霉素衍生物
WO2003004509A2 (en) * 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US6515116B2 (en) * 2000-03-15 2003-02-04 Hanmi Pharm. Co., Method of preparing form II crystals of clarithromycin

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
DE69733439T2 (de) 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
KR20010013660A (ko) 1997-06-11 2001-02-26 실버스타인 아써 에이. 9-옥심 에리트로마이신 유도체
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
DK1147121T3 (da) 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
JP2000351794A (ja) * 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
EP1478404A1 (en) 2002-02-22 2004-11-24 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
EP1553954A4 (en) 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US7332476B2 (en) 2003-04-25 2008-02-19 Novartis Ag Pyridyl substituted ketolide antibiotics
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
EP1628989B1 (en) * 2003-05-13 2006-12-20 Glaxo Group Limited Novel 14 and 15 membered-ring compounds
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ATE373009T1 (de) 2004-04-28 2007-09-15 Alembic Ltd Verfahren zur vorbereitung von telithromycin
AU2005240849B2 (en) 2004-05-06 2008-10-23 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ester linked macrolides useful for the treatment of microbial infections
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
GB0424958D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
CN2756842Y (zh) * 2004-11-12 2006-02-08 胡济荣 沙滩车用一体化发动机
US20080227730A1 (en) 2005-01-14 2008-09-18 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
WO2007008537A2 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
WO2007143507A2 (en) 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
MX2010004389A (es) * 2007-10-23 2010-05-20 Transave Inc Formulaciones de vancomicina liposomales.
AU2008316830B2 (en) * 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) * 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
WO2011112864A1 (en) 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
HRP20160168T1 (hr) 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US20130164351A1 (en) 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1343216A (zh) * 1999-04-08 2002-04-03 北陆制药株式会社 红霉素衍生物
US6515116B2 (en) * 2000-03-15 2003-02-04 Hanmi Pharm. Co., Method of preparing form II crystals of clarithromycin
WO2003004509A2 (en) * 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity

Also Published As

Publication number Publication date
US20130066056A1 (en) 2013-03-14
US20200087335A1 (en) 2020-03-19
IL223161A0 (en) 2013-02-03
DK2571506T3 (en) 2017-08-28
EP2571506B1 (en) 2017-05-10
JP2013527187A (ja) 2013-06-27
US20150232500A1 (en) 2015-08-20
HK1181672A1 (zh) 2013-11-15
KR20130120374A (ko) 2013-11-04
HK1218919A1 (zh) 2017-03-17
SI2571506T1 (sl) 2017-12-29
PL2571506T3 (pl) 2017-10-31
EP2571506A1 (en) 2013-03-27
CN102917708A (zh) 2013-02-06
AU2011255464A1 (en) 2012-12-13
EP2571506A4 (en) 2014-04-02
AU2011255464C1 (en) 2017-02-23
JP6184319B2 (ja) 2017-08-23
BR112012029586A2 (pt) 2016-08-02
AU2011255464B2 (en) 2016-06-16
ES2636948T3 (es) 2017-10-10
WO2011146829A1 (en) 2011-11-24
CA2799937A1 (en) 2011-11-24
RU2608390C2 (ru) 2017-01-18
CN105198944B (zh) 2018-06-01
RU2012150753A (ru) 2014-06-27
US9051346B2 (en) 2015-06-09
CN105198944A (zh) 2015-12-30
US20190048035A1 (en) 2019-02-14
KR101945324B1 (ko) 2019-02-07

Similar Documents

Publication Publication Date Title
CN105198944B (zh) 制备大环内酯和酮内酯及其中间体的方法
US10131684B2 (en) Process for the preparation of macrolide antibacterial agents
PL213731B1 (pl) Sposób wytwarzania pochodnej 4"-podstawionej-9-deoksy-9A-aza-9A-homoerytromecyny
JP2015038095A (ja) 抗菌活性を有する６−ｏ−置換ケトリド
HUP0004085A2 (hu) A 9a-azaleidek csoportjához tartozó, új 3,6-hemiketálszármazékok
EP0124216B1 (en) C-20- and c-23-modified macrolide derivatives
CA1234807A (en) C-20- and c-23-modified macrolide derivatives
US20090111760A1 (en) Macrolone compounds
CN101074252B (zh) 11,12-环碳酸酯-阿奇霉素4＂-氨甲酸酯衍生物、制备方法及其药物组合物
JP2001515844A (ja) ３−デスクラジノース６−ｏ−置換エリスロマイシン誘導体
HK1218919B (en) Processes for preparing macrolides and ketolides and intermediates therefor
HK1181672B (en) Processes for preparing macrolides and ketolides and intermediates therefor
BG62333B1 (bg) Нови съединения от клас секомакролиди и секоазалиди и методза получаването им
US7410952B2 (en) Derivatives of azithromycin
HK1183432B (en) Processes for preparing macrolides and ketolides and intermediates therefor
HK1183432A (en) Processes for preparing macrolides and ketolides and intermediates therefor
JPH0136834B2 (cg-RX-API-DMAC10.html)
US20050164958A1 (en) O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
JP2001072699A (ja) マクロライド系化合物
WO1998040393A1 (fr) Nouveaux derives du mycaminosyltylonolide
HUT74073A (en) New compounds of the secomacrolide and secoazalide class and a process for the preparation thereof
JP2007223900A (ja) ６−ｏ−置換ケトライド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181672

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1181672

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20200520